Brief: Edgewise Therapeutics Begins Dosing First-In-Human Phase 1 Trial Of EDG-7500
14/09/2023 13:18
Sept 14 (Reuters) - Edgewise Therapeutics Inc EWTX.O :
* EDGEWISE THERAPEUTICS BEGINS DOSING FIRST-IN-HUMAN PHASE 1
TRIAL
OF EDG-7500, ITS LEAD CLINICAL CANDIDATE FOR HYPERTROPHIC
CARDIOMYOPATHY (HCM) AND OTHER SERIOUS DISEASES OF CARDIAC
DIASTOLIC DYSFUNCTION
* EDGEWISE THERAPEUTICS INC - PLANNING TO BEGIN A PHASE 1B
STUDY
OF EDG-7500 IN INDIVIDUALS WITH OBSTRUCTIVE HCM IN FIRST HALF OF
2024
Source text for Eikon: ID:nBw1qp9Mza
Further company coverage: EWTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending